Need for a realistic appraisal of benzodiazepines

World Psychiatry

Volumn 14, Issue 2, 2015, Pages 243-244

  Balon, Richard ^a   Fava, Giovanni A ^b,c   Rickels, Karl ^d  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY AT BUFFALO   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; BENZODIAZEPINE DERIVATIVE; CONTROLLED SUBSTANCE; HYPNOTIC AGENT; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR;

AGE; ALZHEIMER DISEASE; ANXIETY DISORDER; BENZODIAZEPINE DEPENDENCE; DEMENTIA; DEPRESSION; DRUG ABUSE; DRUG CONTROL; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; FALL RISK; GENERALIZED ANXIETY DISORDER; HUMAN; INSOMNIA; LETTER; PANIC; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; SEX DIFFERENCE; SIDE EFFECT; TRAFFIC ACCIDENT;

EID: 84930453876     PISSN: 17238617     EISSN: 20515545     Source Type: Journal    
DOI: 10.1002/wps.20219     Document Type: Letter

References (17)

1. Olfson M, King M, Schoenfeld M,. Benzodiazepine use in the United States. JAMA Psychiatry 2015; 72: 136-42.
2. Billioti de Gage S, Moride Y, Ducruet T, et al., Benzodiazepine use and risk of Alzheimer's disease: case control study. BMJ 2014; 349: g5205.
3. Moore N, Pariente A, Begaud B,. Why are benzodiazepines not yet controlled substances? JAMA Psychiatry 2015; 72: 110-1.
4. National Institute for Clinical Excellence. Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia. London: National Institute for Clinical Excellence, 2004.
5. Walsh JK, Krystal AD, Amato DA, et al., Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep 2007; 30: 959-68.
6. Krystal AD, Erman M, Zammit GK, et al., Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo controlled, parallel-group, multicenter study. Sleep 2008; 31: 79-90.
7. Sivertsen B, Salo P, Mykletun A, et al., The bidirectional association between depression and insomnia: the HUNT study. Psychosom Med 2012; 74: 758-65.
8. Greenblatt DJ, Shader RI, Abernethy DR,. Current status of benzodiazepines (first of two parts). N Engl J Med 1983; 309: 354-8.
9. Greenblatt DJ, Shader RI, Abernethy DR,. Current status of benzodiazepines (second of two parts). N Engl J Med 1983; 309: 410-6.
10. Starcevic V,. The reappraisal of benzodiazepines in the treatment of anxiety and related disorders. Expert Rev Neurother 2014; 14: 1275-86.
11. Offidani E, Guidi J, Tomba E, et al., Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: a systematic review and meta-analysis. Psychother Psychosom 2013; 82: 355-62.
12. Nardi AE, Valenca AM, Freire RC, et al., Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine. Braz J Med Biol Res 2011; 44: 366-73.
13. Nardi AE, Freire RC, Mochcovitch MD, et al., A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine. J Clin Psychopharmacol 2102; 32: 120-6.
14. American Psychiatric Association Task Force on Benzodiazepine Dependency. Benzodiazepine dependence, toxicity, and abuse. Washington: American Psychiatric Association, 1990.
15. Nielsen M, Hansen EH, Gotzsche PC,. What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors. Addiction 2011; 107: 900-8.
16. Cerovecki A, Musil R, Klimke A, et al., Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. CNS Drugs 2013; 27: 545-72.
17. Salzman C, Shader RI,. Benzodiazepine use and risk for Alzheimer disease. J Clin Psychopharmacol 2015; 35: 1-3.